Amicus Therapeutics (FOLD) EBIAT: 2009-2025
Historic EBIAT for Amicus Therapeutics (FOLD) over the last 16 years, with Sep 2025 value amounting to $17.3 million.
- Amicus Therapeutics' EBIAT rose 357.19% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.1 million, marking a year-over-year increase of 86.57%. This contributed to the annual value of -$56.1 million for FY2024, which is 62.99% up from last year.
- Per Amicus Therapeutics' latest filing, its EBIAT stood at $17.3 million for Q3 2025, which was up 170.87% from -$24.4 million recorded in Q2 2025.
- Amicus Therapeutics' EBIAT's 5-year high stood at $17.3 million during Q3 2025, with a 5-year trough of -$85.3 million in Q1 2022.
- In the last 3 years, Amicus Therapeutics' EBIAT had a median value of -$21.7 million in 2025 and averaged -$21.5 million.
- Examining YoY changes over the last 5 years, Amicus Therapeutics' EBIAT showed a top increase of 357.19% in 2025 and a maximum decrease of 55.57% in 2025.
- Amicus Therapeutics' EBIAT (Quarterly) stood at -$83.3 million in 2021, then soared by 32.92% to -$55.9 million in 2022, then skyrocketed by 39.42% to -$33.8 million in 2023, then surged by 143.55% to $14.7 million in 2024, then skyrocketed by 357.19% to $17.3 million in 2025.
- Its EBIAT stands at $17.3 million for Q3 2025, versus -$24.4 million for Q2 2025 and -$21.7 million for Q1 2025.